靶向急性髓系白血病中的葡萄糖转运蛋白1以克服阿糖胞苷耐药性。 - Suppr

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.

作者信息

Åbacka Hannah, Hansen Jesper S, Huang Peng, Venskutonytė Raminta, Hyrenius-Wittsten Axel, Poli Giulio, Tuccinardi Tiziano, Granchi Carlotta, Minutolo Filippo, Hagström-Andersson Anna K, Lindkvist-Petersson Karin

机构信息

Dept. of Experimental Medical Science, Medical Structural Biology, Lund University, Sweden.

Dept. of Laboratory Medicine, Division of Clinical Genetics, Lund University, Sweden.

出版信息

Haematologica. 2021 Apr 1;106(4):1163-1166. doi: 10.3324/haematol.2020.246843.

DOI:10.3324/haematol.2020.246843

PMID:32554563

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8018118/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aee9/8018118/676b4e7b55da/1061163.fig1.jpg

相似文献

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.

Haematologica. 2021 Apr 1;106(4):1163-1166. doi: 10.3324/haematol.2020.246843.

Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.

Int J Hematol. 1999 Jul;70(1):56-7.

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.

Blood. 2013 Jan 3;121(1):26-8. doi: 10.1182/blood-2012-07-444851.

A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.

Leukemia. 2007 May;21(5):1093-7. doi: 10.1038/sj.leu.2404595. Epub 2007 Feb 15.

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.

Blood. 2017 Aug 17;130(7):946-948. doi: 10.1182/blood-2017-04-777722. Epub 2017 Jul 5.

Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.

Pediatr Blood Cancer. 2024 Jun;71(6):e30974. doi: 10.1002/pbc.30974. Epub 2024 Mar 24.

Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients.

AIDS. 1998 Jan 22;12(2):221-2.

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.

Leukemia. 2021 Feb;35(2):295-298. doi: 10.1038/s41375-020-01110-3. Epub 2020 Dec 16.

High-dose cytarabine induction for acute myeloid leukemia.

Blood. 1996 Jul 15;88(2):754-5.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

引用本文的文献

Disulfidptosis in tumor progression.

Cell Death Discov. 2025 Apr 28;11(1):205. doi: 10.1038/s41420-025-02495-9.

Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.

Ann Hematol. 2024 Dec;103(12):4883-4899. doi: 10.1007/s00277-024-06117-9. Epub 2024 Nov 28.

Glycolysis and chemoresistance in acute myeloid leukemia.

Heliyon. 2024 Aug 2;10(15):e35721. doi: 10.1016/j.heliyon.2024.e35721. eCollection 2024 Aug 15.

Metabolic dependencies of acute myeloid leukemia stem cells.

Int J Hematol. 2024 Oct;120(4):427-438. doi: 10.1007/s12185-024-03789-x. Epub 2024 May 15.

SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia.

Sci Rep. 2024 Apr 20;14(1):9104. doi: 10.1038/s41598-024-58689-1.

Curcumin Inhibits the PPARδ-p-Akt-GLUT1 Pathway and Ameliorates the Antiproliferative Effects of Doxorubicin in MDA-MB-231 Cells.

Asian Pac J Cancer Prev. 2024 Mar 1;25(3):1035-1043. doi: 10.31557/APJCP.2024.25.3.1035.

Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy.

Redox Biol. 2023 Dec;68:102966. doi: 10.1016/j.redox.2023.102966. Epub 2023 Nov 19.

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.

Clin Epigenetics. 2023 Sep 13;15(1):150. doi: 10.1186/s13148-023-01566-x.

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity.

Blood Adv. 2023 Sep 26;7(18):5382-5395. doi: 10.1182/bloodadvances.2023009967.

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.

J Exp Clin Cancer Res. 2022 Dec 9;41(1):340. doi: 10.1186/s13046-022-02542-8.

本文引用的文献

New insights into GluT1 mechanics during glucose transfer.

Sci Rep. 2019 Jan 30;9(1):998. doi: 10.1038/s41598-018-37367-z.

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.

Haematologica. 2018 Sep;103(9):1472-1483. doi: 10.3324/haematol.2018.188185. Epub 2018 Jun 7.

Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.

Leuk Res. 2017 Sep;60:44-52. doi: 10.1016/j.leukres.2017.06.007. Epub 2017 Jun 16.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.

J Hematol Oncol. 2017 Jan 6;10(1):9. doi: 10.1186/s13045-016-0371-1.

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.

Cell. 2016 Sep 22;167(1):171-186.e15. doi: 10.1016/j.cell.2016.08.057. Epub 2016 Sep 15.

Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4711-6. doi: 10.1073/pnas.1603735113. Epub 2016 Apr 12.

AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.

Cell Stem Cell. 2015 Nov 5;17(5):585-96. doi: 10.1016/j.stem.2015.08.019. Epub 2015 Oct 1.

Salicylketoximes That Target Glucose Transporter 1 Restrict Energy Supply to Lung Cancer Cells.

ChemMedChem. 2015 Nov;10(11):1892-900. doi: 10.1002/cmdc.201500320. Epub 2015 Sep 1.

Glucose transport machinery reconstituted in cell models.

Chem Commun (Camb). 2015 Feb 11;51(12):2316-9. doi: 10.1039/c4cc08838g.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.

作者信息

机构信息

Dept. of Experimental Medical Science, Medical Structural Biology, Lund University, Sweden.

Dept. of Laboratory Medicine, Division of Clinical Genetics, Lund University, Sweden.

出版信息

Haematologica. 2021 Apr 1;106(4):1163-1166. doi: 10.3324/haematol.2020.246843.

DOI:10.3324/haematol.2020.246843

PMID:32554563

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8018118/

Abstract

摘要

相似文献

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.

Haematologica. 2021 Apr 1;106(4):1163-1166. doi: 10.3324/haematol.2020.246843.

Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.

Int J Hematol. 1999 Jul;70(1):56-7.

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.

Blood. 2013 Jan 3;121(1):26-8. doi: 10.1182/blood-2012-07-444851.

A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.

Leukemia. 2007 May;21(5):1093-7. doi: 10.1038/sj.leu.2404595. Epub 2007 Feb 15.

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.

Blood. 2017 Aug 17;130(7):946-948. doi: 10.1182/blood-2017-04-777722. Epub 2017 Jul 5.

Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.

Pediatr Blood Cancer. 2024 Jun;71(6):e30974. doi: 10.1002/pbc.30974. Epub 2024 Mar 24.

Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients.

AIDS. 1998 Jan 22;12(2):221-2.

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.

Leukemia. 2021 Feb;35(2):295-298. doi: 10.1038/s41375-020-01110-3. Epub 2020 Dec 16.

High-dose cytarabine induction for acute myeloid leukemia.

Blood. 1996 Jul 15;88(2):754-5.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

引用本文的文献

Disulfidptosis in tumor progression.

Cell Death Discov. 2025 Apr 28;11(1):205. doi: 10.1038/s41420-025-02495-9.

Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.

Ann Hematol. 2024 Dec;103(12):4883-4899. doi: 10.1007/s00277-024-06117-9. Epub 2024 Nov 28.

Glycolysis and chemoresistance in acute myeloid leukemia.

Heliyon. 2024 Aug 2;10(15):e35721. doi: 10.1016/j.heliyon.2024.e35721. eCollection 2024 Aug 15.

Metabolic dependencies of acute myeloid leukemia stem cells.

Int J Hematol. 2024 Oct;120(4):427-438. doi: 10.1007/s12185-024-03789-x. Epub 2024 May 15.

SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia.

Sci Rep. 2024 Apr 20;14(1):9104. doi: 10.1038/s41598-024-58689-1.

Curcumin Inhibits the PPARδ-p-Akt-GLUT1 Pathway and Ameliorates the Antiproliferative Effects of Doxorubicin in MDA-MB-231 Cells.

Asian Pac J Cancer Prev. 2024 Mar 1;25(3):1035-1043. doi: 10.31557/APJCP.2024.25.3.1035.

Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy.

Redox Biol. 2023 Dec;68:102966. doi: 10.1016/j.redox.2023.102966. Epub 2023 Nov 19.

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.

Clin Epigenetics. 2023 Sep 13;15(1):150. doi: 10.1186/s13148-023-01566-x.

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity.

Blood Adv. 2023 Sep 26;7(18):5382-5395. doi: 10.1182/bloodadvances.2023009967.

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.

J Exp Clin Cancer Res. 2022 Dec 9;41(1):340. doi: 10.1186/s13046-022-02542-8.

本文引用的文献

New insights into GluT1 mechanics during glucose transfer.

Sci Rep. 2019 Jan 30;9(1):998. doi: 10.1038/s41598-018-37367-z.

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.

Haematologica. 2018 Sep;103(9):1472-1483. doi: 10.3324/haematol.2018.188185. Epub 2018 Jun 7.

Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.

Leuk Res. 2017 Sep;60:44-52. doi: 10.1016/j.leukres.2017.06.007. Epub 2017 Jun 16.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.

J Hematol Oncol. 2017 Jan 6;10(1):9. doi: 10.1186/s13045-016-0371-1.

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.

Cell. 2016 Sep 22;167(1):171-186.e15. doi: 10.1016/j.cell.2016.08.057. Epub 2016 Sep 15.

Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4711-6. doi: 10.1073/pnas.1603735113. Epub 2016 Apr 12.

AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.

Cell Stem Cell. 2015 Nov 5;17(5):585-96. doi: 10.1016/j.stem.2015.08.019. Epub 2015 Oct 1.

Salicylketoximes That Target Glucose Transporter 1 Restrict Energy Supply to Lung Cancer Cells.

ChemMedChem. 2015 Nov;10(11):1892-900. doi: 10.1002/cmdc.201500320. Epub 2015 Sep 1.

Glucose transport machinery reconstituted in cell models.

Chem Commun (Camb). 2015 Feb 11;51(12):2316-9. doi: 10.1039/c4cc08838g.

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献